Gastric cancer is one of the leading causes of cancer deaths worldwide. A new molecular classification based on comprehensive genomic analysis is currently replacing the old, clinically pointless classification. This classification based on targetable genomic abnormalities and pathway amplifications may open avenues for clinical research based on targeted medications and strategies. We review three important potential targets in advanced gastric cancer.

(BELG J MED ONCOL 2016;10(7):243–248)